Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Axcella Health Inc | AXLA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
4.58 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 2.5875 - 41.25 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 4.58 | USD |
Axcella Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 13.50M | - | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Axcella Health News
Date | Time | Source | News Article |
---|---|---|---|
12/22/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
11/17/2023 | 15:45 | Edgar (US Regulatory) | Form 8-K - Current report |
11/17/2023 | 07:47 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in.. |
11/17/2023 | 07:46 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in.. |
11/17/2023 | 07:28 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
11/09/2023 | 15:45 | Edgar (US Regulatory) | Form 8-K - Current report |
11/06/2023 | 08:22 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
11/01/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
10/06/2023 | 15:47 | Edgar (US Regulatory) | Form 8-K - Current report |
9/18/2023 | 15:31 | Edgar (US Regulatory) | Form 8-K - Current report |
9/14/2023 | 15:31 | Edgar (US Regulatory) | Form 8-K - Current report |
9/14/2023 | 15:30 | Business Wire | Axcella Announces Reverse Stock Split Effective September.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AXLA Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 6.65 | 12.42 | 4.07 | 10.07 | 239,018 | -2.07 | -31.13% |
1 Year | 11.50 | 41.25 | 2.5875 | 15.77 | 7,681,925 | -6.92 | -60.17% |
3 Years | 121.25 | 147.50 | 2.5875 | 18.13 | 2,152,797 | -116.67 | -96.22% |
5 Years | 378.00 | 398.50 | 2.5875 | 22.70 | 1,302,062 | -373.42 | -98.79% |
Axcella Health Description
Axcella Health Inc a biotechnology company focused on treating complex diseases and improve health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company's pipeline includes lead therapeutic candidates, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125 for non-alcoholic steatohepatitis. |